Editorial

newsfeed

We have compiled a pre-selection of editorial content for you, provided by media companies, publishers, stock exchange services and financial blogs. Here you can get a quick overview of the topics that are of public interest at the moment.
360o
Share this page
News from the economy, politics and the financial markets
In this section of our news section we provide you with editorial content from leading publishers.

TRENDING

Latest news

Federal Life Insurance Company Announces Acquisition of Texas Service Life Insurance Company, Signaling a New Era in Preneed Insurance

AUSTIN, Texas, June 04, 2025 (GLOBE NEWSWIRE) --  Federal Life Insurance Company has completed the acquisition of Texas Service Life Insurance Company, a leader in preneed insurance, marking a bold step forward for the industry. This strategic move underscores Federal Life’s commitment to expanding growth pathways and forward-thinking solutions that empower families to plan with confidence. With an A- (Excellent) rating from AM Best, and backed by leading investment firm, Bain Capital, Federal Life is in a strong financial position to collaboratively build a new future for preneed insurance. "This is more than an acquisition, it’s a signal to the market that preneed is an essential product for families and we believe the market is underserved," said Knut Olson, CEO of Federal Life with over 20 years of experience in the insurance industry. "We are reimagining how families prepare for the future by delivering exceptional service and innovative opportunities to access preplanning. Our team is ready to push boundaries, drive industry change, and ensure families receive the support they deserve." Following the acquisition, George Wise steps in as President of Texas Service Life, leading the charge toward a national expansion strategy that prioritizes accessibility, trust, and cutting-edge financial security for families across the country. "We are evolving with purpose, ready to strengthen and scale a business designed to meet the ever-changing needs of families everywhere," Wise stated. "The future of preneed planning is here, and we’re shaping it with fresh ideas, dynamic solutions, and a commitment to delivering lasting value.” Federal Life and Texas Service Life are committed to building better products, exceeding service expectations, and helping funeral homes and families evolve in an ever-changing world. Together, they embody a more creative, dynamic, future-forward vision for preneed insurance. About Federal Life Insurance CompanyFederal Life Insurance Company is shaping the future of insurance with innovative solutions designed to protect individuals and families at every stage of life. Rooted in financial strength and stability, Federal Life is committed to delivering reliable accident & health and life products that evolve with its clients’ changing needs. As the company expands its reach and enhances its offerings, the focus remains on providing trusted, forward-thinking coverage that empowers financial security for generations to come. About Texas Service Life Insurance CompanyTexas Service Life Insurance Company has been serving customers since 1985. With a proven track record in the industry and a robust financial foundation, Texas Service Life consistently delivers the dependability families require when planning their insurance arrangements. Family1® is a Registered Trademark of Texas Service Life Insurance Company, Austin, TX. Media Contact:Jessica GrannChief Marketing and Culture OfficerFederal Life Insurance Companyjgrann@federallife.com The post Federal Life Insurance Company Announces Acquisition of Texas Service Life Insurance Company, Signaling a New Era in Preneed Insurance appeared first on ForexTV.

Read More

The Gross Law Firm Notifies Shareholders of Strategy Incorporated (MSTR) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Strategy Incorporated (NASDAQ: MSTR). Shareholders who purchased shares of MSTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/strategy-incorporated-loss-submission-form/?id=150966&from=3 CLASS PERIOD: April 30, 2024 to April 4, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the anticipated profitability of the Company’s bitcoin-focused investment strategy and treasury operations was overstated; (ii) the various risks associated with bitcoin’s volatility and the magnitude of losses Strategy could recognize on the value of its digital assets following its adoption of ASU 2023-08 were understated; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times. DEADLINE: July 15, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/strategy-incorporated-loss-submission-form/?id=150966&from=3  NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of MSTR during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 15, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.com Phone: (646) 453-8903 The post The Gross Law Firm Notifies Shareholders of Strategy Incorporated (MSTR) of a Class Action Lawsuit and an Upcoming Deadline appeared first on ForexTV.

Read More

Global AI in Remote Patient Monitoring Market to Cross USD 13 Billion by 2032 | DelveInsight

The AI in remote patient monitoring market is witnessing strong growth, driven by the increasing prevalence of chronic illnesses like cancer, cardiovascular conditions, and lifestyle-related disorders. This momentum is further boosted by a rise in product innovation, growing global investments in digital health infrastructure, and a heightened focus on proactive, data-centric healthcare approaches. These trends are anticipated to significantly accelerate the expansion of the AI-enabled RPM market throughout the forecast period of 2025 to 2032. New York, USA, June 04, 2025 (GLOBE NEWSWIRE) -- Global AI in Remote Patient Monitoring Market to Cross USD 13 Billion by 2032 | DelveInsight The AI in remote patient monitoring market is witnessing strong growth, driven by the increasing prevalence of chronic illnesses like cancer, cardiovascular conditions, and lifestyle-related disorders. This momentum is further boosted by a rise in product innovation, growing global investments in digital health infrastructure, and a heightened focus on proactive, data-centric healthcare approaches. These trends are anticipated to significantly accelerate the expansion of the AI-enabled RPM market throughout the forecast period of 2025 to 2032. DelveInsight’s AI in Remote Patient Monitoring Market Insights report provides the current and forecast market analysis, individual leading AI in remote patient monitoring companies’ market shares, challenges, AI in remote patient monitoring market drivers, barriers, trends, and key market AI in remote patient monitoring companies in the market. Key Takeaways from the AI in Remote Patient Monitoring Market Report As per DelveInsight estimates, North America is anticipated to dominate the global AI in remote patient monitoring market during the forecast period.  In the product type segment of the AI in remote patient monitoring market, the devices category held the largest revenue share in 2024. Notable AI in remote patient monitoring companies such as Medtronic, iRhythm Inc., Koninklijke Philips N.V., Siemens Healthineers, GE HealthCare, Apple Inc., AliveCor Inc., Biofourmis, Optum, Inc., Headspace Health, Withings, NeuroRPM Inc., Caretaker Medical, Implicity, Stryker, Biobeat, and several others are currently operating in the AI in remote patient monitoring market. In September 2024, iRhythm Technologies announced the Japanese regulatory approval of the zio® ECG monitoring system, the first product to deliver arrhythmia monitoring service utilizing artificial intelligence. In April 2024, Royal Philips, a global leader in health technology, announced a strategic partnership to integrate smartQare’s advanced solution, viQtor, with Philips’ world-leading clinical patient monitoring platforms. This collaboration aims to enable the next generation of continuous patient monitoring both in and out of the hospital, starting in Europe. To read more about the latest highlights related to the AI in remote patient monitoring market, get a snapshot of the key highlights entailed in the Global AI in Remote Patient Monitoring Market Report AI in Remote Patient Monitoring Overview Artificial intelligence (AI) is revolutionizing remote patient monitoring (RPM) by enabling real-time, continuous health surveillance outside of traditional clinical settings. Through wearable devices and connected sensors, AI algorithms can analyze vital signs, detect anomalies, and predict potential health deterioration before symptoms become critical. This proactive approach allows for early interventions, reduces hospital readmissions, and improves chronic disease management, particularly for conditions like heart failure, diabetes, and COPD. By automating data analysis and triage, AI also significantly reduces the burden on healthcare professionals, allowing them to focus on patients who need urgent attention. Furthermore, AI-driven RPM fosters personalized care by learning from individual patient data over time. Machine learning models can adapt to each patient’s unique health patterns, improving the accuracy of predictions and enabling tailored treatment plans. Natural language processing (NLP) tools can also interpret patient-reported symptoms via apps or voice interfaces, enriching the clinical picture. As AI technologies evolve, their integration into RPM systems is expected to enhance accessibility, especially in rural or underserved areas, bridging gaps in healthcare delivery while maintaining cost-efficiency and high-quality care. AI in Remote Patient Monitoring Market Insights North America is projected to lead the AI in remote patient monitoring market from 2025 to 2032. This dominance is largely driven by factors such as the growing prevalence of chronic diseases like cancer, a robust healthcare infrastructure, widespread adoption of digital health technologies, and supportive government initiatives. The region also benefits from significant investments in digital health and the extensive use of wearable and connected medical devices. The rising incidence of cancer in the U.S. and Canada is fueling the demand for continuous, home-based care solutions. This trend is accelerating the adoption of AI-driven remote patient monitoring, which enhances treatment management, symptom tracking, and patient outcomes outside traditional healthcare settings. Additionally, the increasing rates of cardiovascular diseases and related risk factors are heightening the need for ongoing and efficient monitoring solutions. AI-powered remote monitoring enables early detection, real-time intervention, and personalized care for heart patients, particularly in aging populations, thereby reducing complications and improving outcomes. Together, these factors create a favorable landscape for market expansion, solidifying North America’s position as the leading region in the AI-based remote patient monitoring market throughout the forecast period. To know more about why North America is leading the market growth in the AI in remote patient monitoring market, get a snapshot of the AI in Remote Patient Monitoring Market Outlook  AI in Remote Patient Monitoring Market Dynamics The AI in remote patient monitoring market is undergoing rapid transformation, driven by the convergence of advanced technologies, shifting healthcare models, and an increasing emphasis on personalized care. Artificial Intelligence is enhancing RPM systems by enabling real-time data analysis, predictive analytics, and automation, thereby helping providers manage chronic diseases, post-operative care, and elderly patients more effectively. AI algorithms can analyze vast volumes of patient data from wearable devices and home-based monitoring systems, identifying anomalies and alerting care teams before a crisis occurs. This proactive capability is fueling demand, particularly in value-based care models where preventing hospital readmissions is key. One of the primary drivers of this market is the global increase in chronic diseases and aging populations, which has led to an urgent need for continuous and cost-effective patient monitoring. AI-based RPM solutions not only reduce the burden on healthcare systems but also empower patients to manage their conditions better. Furthermore, the COVID-19 pandemic accelerated adoption, normalizing virtual care and remote diagnostics. This shift has continued post-pandemic, with healthcare providers and payers increasingly investing in AI-driven tools to support hybrid care models and decentralize service delivery. However, the market is not without its challenges. Data privacy, regulatory hurdles, and interoperability issues are key barriers to widespread adoption. The effectiveness of AI algorithms depends heavily on access to high-quality, diverse datasets, and data silos across healthcare institutions can limit this. Additionally, regulatory frameworks are still evolving to keep pace with AI's rapid advancement, and there's ongoing scrutiny about algorithmic bias and accountability. Addressing these challenges is crucial for building trust among clinicians and patients alike. On the competitive front, the market is witnessing intense innovation and strategic partnerships among tech firms, medtech companies, and healthcare providers. Startups are emerging with specialized AI capabilities in areas like arrhythmia detection, diabetic monitoring, and mental health assessment, while major players are integrating AI into their existing RPM platforms. Cloud infrastructure providers and AI-as-a-service vendors are also playing a key role in scaling solutions across geographies. Looking ahead, the AI in RPM market is expected to experience sustained growth, driven by advances in sensor technology, 5G connectivity, and federated learning models that allow privacy-preserving data sharing. As AI becomes more explainable and transparent, its integration into clinical workflows will deepen, making remote monitoring an integral part of mainstream healthcare delivery. Get a sneak peek at the AI in remote patient monitoring market dynamics @ AI in Remote Patient Monitoring Market Dynamic Analysis  Report Metrics Details Coverage Global Study Period 2022–2032 AI in Remote Patient Monitoring Market CAGR ~27% AI in Remote Patient Monitoring Market Size by 2032 USD 13.1 Billion Key AI in Remote Patient Monitoring Companies Medtronic, iRhythm Inc., Koninklijke Philips N.V., Siemens Healthineers, GE HealthCare, Apple Inc., AliveCor Inc., Biofourmis, Optum, Inc., Headspace Health, Withings, NeuroRPM Inc., Caretaker Medical, Implicity, Stryker, Biobeat, among others AI in Remote Patient Monitoring Market Assessment AI in Remote Patient Monitoring Market Segmentation AI in Remote Patient Monitoring Market Segmentation By Product Type: Devices, Software, and Services AI in Remote Patient Monitoring Market Segmentation By Application: Cancer, Cardiovascular Disorder, Lifestyle Disorders, and Others AI in Remote Patient Monitoring Market Segmentation By End User: Hospitals and Clinics, Diagnostic Centers, and Homecare Setting AI in Remote Patient Monitoring Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View Which MedTech key players in the AI in remote patient monitoring market are set to emerge as the trendsetter explore @ AI in Remote Patient Monitoring Companies  Table of Contents  1 AI in Remote Patient Monitoring Market Report Introduction 2 AI in Remote Patient Monitoring Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 AI in Remote Patient Monitoring Market Key Factors Analysis 6 AI in Remote Patient Monitoring Market Porter’s Five Forces Analysis 7 AI in Remote Patient Monitoring Market Layout 8 AI in Remote Patient Monitoring Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the AI in remote patient monitoring market by 2032? Click to get a snapshot of the AI in Remote Patient Monitoring Market Trends Related Reports Patient Monitoring Devices Market Patient Monitoring Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key patient monitoring devices companies, including Medtronic plc, GE Healthcare, Philips Healthcare, Abbott Laboratories, Siemens Healthineers, Nihon Kohden Corporation, Masimo Corporation, Omron Healthcare Co., Ltd., Smiths Medical, Hillrom, Welch Allyn, Inc., Natus Medical Incorporated, Mindray Medical International Limited, Nonin Medical, Inc., Spacelabs Healthcare, among others. Artificial Intelligence in Drug Commercialization Market Artificial Intelligence in Drug Commercialization Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in drug commercialization companies, including EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., among others. Artificial Intelligence in Precision Medicine Market Artificial Intelligence in Precision Medicine Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in precision medicine companies, including TEMPUS, GE HealthCare, Qure.ai, Envisionit Deep AI (Pty) Ltd., Avicenna.AI, Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., among others. Artificial Intelligence In Drug Discovery Market Artificial Intelligence In Drug Discovery Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in drug discovery companies, including IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Atomwise Inc, Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), Insilico Medicine, BenevolentAI, Exscientia, Cyclia, Valo Health, Owkin Inc, Verge Genomics, BioSymetrics, among others. Artificial Intelligence in Medical Imaging Market Artificial Intelligence in Medical Imaging Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in medical imaging companies, including Microsoft, Siemens Healthineers, GE Healthcare, NVIDIA Corporation, Philips Healthcare, Arterys, Butterfly Network, Enlitic, HeartFlow, Digital Diagnostics, among others. DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.   CONTACT: Contact Us Shruti Thakur  info@delveinsight.com  +14699457679  The post Global AI in Remote Patient Monitoring Market to Cross USD 13 Billion by 2032 | DelveInsight appeared first on ForexTV.

Read More

The Gross Law Firm Reminds BigBear.ai Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 10, 2025 – BBAI

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of BigBear.ai Holdings, Inc. (NYSE: BBAI). Shareholders who purchased shares of BBAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/bigbear-ai-holdings-inc-loss-submission-form/?id=150964&from=3 CLASS PERIOD: March 31, 2022 to March 25, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) BigBear maintained deficient accounting review policies related to the reporting and disclosure of certain non-routine, unusual, or complex transactions; (ii) as a result, the Company incorrectly determined that the conversion option within the 2026 Convertible Notes qualified for the derivative scope exception under ASC 815-40 and failed to bifurcate the conversion option as required by ASC 815-15; (iii) accordingly, BigBear had improperly accounted for the 2026 Convertible Notes; (iv) the foregoing error caused BigBear to misstate various items in several of the Company’s previously issued financial statements; (v) as a result, these financial statements were inaccurate and would likely need to be restated; (vi) BigBear would require extra time and expense to correct the inaccurate financial statements, thereby increasing the risk that the Company would be unable to timely file certain financial reports with the SEC; and (vii) as a result, the Company’s public statements were materially false and misleading at all relevant times. DEADLINE: June 10, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/bigbear-ai-holdings-inc-loss-submission-form/?id=150964&from=3  NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of BBAI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 10, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.com Phone: (646) 453-8903 The post The Gross Law Firm Reminds BigBear.ai Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 10, 2025 – BBAI appeared first on ForexTV.

Read More

The Gross Law Firm Notifies Shareholders of DoubleVerify Holdings, Inc.(DV) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DoubleVerify Holdings, Inc. (NYSE: DV). Shareholders who purchased shares of DV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/doubleverify-holdings-inc-loss-submission-form-2/?id=150961&from=3 CLASS PERIOD: November 10, 2023 to February 27, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) DoubleVerify’s customers were shifting their ad spending from open exchanges to closed platforms, where the Company’s technological capabilities were limited and competed directly with native tools provided by platforms like Meta Platforms and Amazon; (b) DoubleVerify’s ability to monetize on its Activation Services was limited because the development of its technology for closed platforms was significantly more expensive and time-consuming than disclosed to investors; (c) DoubleVerify’s Activation Services in connection with certain closed platforms would take several years to monetize; (d) DoubleVerify’s competitors were better positioned to incorporate AI into their offerings on closed platforms, which impaired DoubleVerify’s ability to compete effectively and adversely impacted the Company’s profits; (e) DoubleVerify systematically overbilled its customers for ad impressions served to declared bots operating out of known data center server farms; (f) DoubleVerify’s risk disclosures were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities; and (g) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. DEADLINE: July 21, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/doubleverify-holdings-inc-loss-submission-form-2/?id=150961&from=3  NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of DV during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 21, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.com Phone: (646) 453-8903 The post The Gross Law Firm Notifies Shareholders of DoubleVerify Holdings, Inc.(DV) of a Class Action Lawsuit and an Upcoming Deadline appeared first on ForexTV.

Read More

Investors in Bitfarms Ltd. Should Contact The Gross Law Firm Before July 8, 2025 to Discuss Your Rights – BITF

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Bitfarms Ltd. (NASDAQ: BITF). Shareholders who purchased shares of BITF during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/bitfarms-ltd-loss-submission-form/?id=150962&from=3 CLASS PERIOD: March 21, 2023 to December 9, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Bitfarms maintained deficient internal controls over financial reporting; (ii) as a result, the Company incorrectly categorized proceeds derived from the sale of digital assets as a cash flow from operating activities rather than as a cash flow from investing activities; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weakness in its internal controls over financial reporting related to its classification of the 2021 Warrants; (iv) the foregoing errors caused Bitfarms to misstate various items in several of the Company’s previously issued financial statements; (v) as a result, these financial statements were inaccurate and would likely need to be restated; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times. DEADLINE: July 8, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/bitfarms-ltd-loss-submission-form/?id=150962&from=3  NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of BITF during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 8, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.com Phone: (646) 453-8903 The post Investors in Bitfarms Ltd. Should Contact The Gross Law Firm Before July 8, 2025 to Discuss Your Rights – BITF appeared first on ForexTV.

Read More

Shareholders that lost money on Ibotta, Inc. (IBTA) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ibotta, Inc. (NYSE: IBTA). Shareholders who purchased shares of IBTA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/ibotta-loss-submission-form/?id=150950&from=3 CLASS PERIOD: This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Ibotta securities pursuant and/or traceable to documents issued in connection with Ibotta’s April 18, 2024 initial public offering. ALLEGATIONS: According to the filed complaint, defendants made false statements and/or concealed that they did not properly warn investors of the risks concerning Ibotta’s contract with The Kroger Co. (“Kroger”). Kroger’s contract was at-will, and Ibotta failed to warn investors that a large client could cancel their contract with Ibotta without warning. Despite providing a detailed explanation of the terms of Ibotta’s contract with Walmart, there was not a single warning of the at-will nature of Kroger’s contract. Rather than disclosing the very real risk of a major client walking away at any time, Ibotta provided boilerplate warnings concerning the importance of maintaining ongoing relationships with their clients. DEADLINE: June 16, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/ibotta-loss-submission-form/?id=150950&from=3  NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of IBTA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 16, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.com Phone: (646) 453-8903 The post Shareholders that lost money on Ibotta, Inc. (IBTA) Urged to Join Class Action – Contact The Gross Law Firm to Learn More appeared first on ForexTV.

Read More

Lost Money on Treace Medical Concepts, Inc. (TMCI)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI). Shareholders who purchased shares of TMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=150952&from=3 CLASS PERIOD: May 8, 2023 to May 7, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the 3D bunion correction system, the “Lapiplasty”; (2) as a result, Treace Medical’s revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function); and (3) defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. DEADLINE: June 10, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=150952&from=3 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of TMCI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 10, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.com Phone: (646) 453-8903 The post Lost Money on Treace Medical Concepts, Inc. (TMCI)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm appeared first on ForexTV.

Read More

Virtus Diversified REIT Announces Acquisition in Sudbury

TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Virtus Capital Corporation, the asset manager of Virtus Diversified REIT (VREIT) is pleased to announce the acquisition of Nickel District Apartments, a 114-unit apartment building located in Sudbury, Ontario. This strategic move significantly enhances the multi-family residential segment of the REIT's portfolio and reinforces its commitment to quality diversified real estate investments. Nickel District Apartments, at 323 Second Avenue, is a wide walk-up style building offering a diverse mix of units to cater to various tenant needs. The property features 1 bachelor unit, 22 one-bedroom apartments, 87 two-bedroom units, and 4 three-bedroom suites. "We are thrilled to add Nickel District Apartments to our growing portfolio," said Aurelio Baglione, CEO of Virtus. "This acquisition aligns perfectly with our strategy of identifying properties with strong fundamentals and potential for value appreciation. The current Net Operating Income aligns with our target yield for investors, while the 21% gap-to-rent presents an excellent opportunity for revenue upside, which we aim to capitalize on responsibly." The property boasts several attractive features such as varied suite styles, including townhouse-style units with separate entrances, terraces, balconies, high ceilings, and some units with two bathrooms. It also features a prime location near major national retailers such as Best Buy, Costco, and Home Depot, enhancing its appeal to tenants. According to Zumper.com, as of April 2025, the median rent for all bedroom counts and property types in Greater Sudbury is $1,899, reflecting a significant increase of 19% over the previous year. This upward trend in rental prices underscores the strong demand for quality housing in the area. Virtus Diversified REIT acquired Nickel District Apartments for $24.35 million. Additionally, the financing for this acquisition will be secured through CMHC-insured mortgages, allowing for favorable mortgage rates that enhance cash flow and overall returns. "Nickel District Apartments is an excellent addition to our multi-family portfolio," commented Josh Will, President of Virtus. "Its strategic location in Sudbury, combined with the potential for increased occupancy, makes it an attractive long-term investment for our unitholders. Our path to growth is not finished yet. We have made it our goal to acquire strong properties from weak hands, and we expect to make some more exciting announcements in the coming months." Virtus Diversified REIT remains committed to building a resilient and diversified portfolio of quality real estate assets across Canada. This acquisition reinforces the REIT's position as a reliable asset manager in the multi-family residential sector and highlights its focus on properties with sound fundamentals and growth potential. For more information about Virtus Diversified REIT and its investment opportunities, please visit www.vreit.ca. About Virtus Diversified REIT Virtus Diversified REIT is focused on acquiring quality properties in strong secondary and tertiary markets across Canada and the United States. The company’s goal is to build a strong and stable commercial, industrial, retail, and multi-unit residential portfolio, enhancing overall portfolio incomes by diversifying the tenant base and geographic diversity. The long-term goal is to maximize the unit value with ongoing management through future acquisitions, repositioning, and competitive financing. Some of Virtus Diversified REIT’s anchor tenants include companies such as Crown Corporation, BJ’s Wholesale Club, The Brick, No Frills, Walmart and Dollarama. Contact Information Josh Willinfo@vreit.cawww.vreit.ca  A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f14c9f0c-e9bb-45dd-9134-dc7277b00b1b The post Virtus Diversified REIT Announces Acquisition in Sudbury appeared first on ForexTV.

Read More

KLĒNR Soaps & Sundries Donates Two Years’ Worth of Premium Soaps to America’s VetDogs

Helping Veterans and First Responders Stay Fresh and Focused While Training with Their Service Dogs KLĒNR Soaps & Sundries Donates Two Years’ Worth of Premium Soaps to America’s VetDogs Service Dog with KLENR Soap Smithtown, New York, June 04, 2025 (GLOBE NEWSWIRE) -- SMITHTOWN, NEW YORK, June 04, 2025 – America’s VetDogs, a national nonprofit that provides service dogs to veterans and first responders free of charge, is excited to announce a partnership with  KLĒNR Soaps & Sundries, a personal care brand that specializes in high-quality, natural soaps and hygiene products. As part of the collaboration, KLĒNR donated two-year’s worth of all-natural, handcrafted bar soap to America’s VetDogs student residences for students to use during their 2-week stay at the facility. KLĒNR was founded in 2022 by Chris Thompson, a decorated Green Beret and active-duty contractor supporting Special Operations. With seven combat deployments under his belt, Thompson founded KLĒNR on his own experience and dedication for resilience, quality, and service. Chris is also a graduate of the America’s VetDogs service dog program where he received his yellow labrador retriever service dog named Major. After facing a difficult transition to civilian life with chronic stress, PTSD, and night terrors, Chris began searching for a service dog. In the fall of 2023, he was matched with Major, a partnership that, in his words, “changed my life in ways I couldn’t have anticipated.” “America’s VetDogs has given so much to me and my family,” said Chris Thompson, founder of KLĒNR Soaps and Sundries. “Not only in the form of paring me with my service dog, Major, but also in the form of their professionalism, kindness, and continued support. It’s my honor to provide soap to the veterans and first responders who come through their program as my small way to saying thank you to them and everyone at America’s VetDogs.” KLĒNR uses natural, organic elements in all their products that are naturally scented, using only scent with essential oils or other plant extracts. Any colorants in the soaps are herbs, herbal extracts, clays, and or mineral compounds. No man-made harmful chemicals. Every veteran and first responder accepted into the service dog program joins America’s VetDogs at their campus in Smithtown, NY where they learn to bond with and train with their new service dog. Now, KLĒNR soap is an essential part of that experience and can be found in all 20 student rooms, ensuring each participant enjoys quality self-care during their stay. It costs more than $50,000 to breed, raise, train, and place one service dog with a veteran or first responder but there is never a charge to the individual. America’s VetDogs depends on the generosity of individuals, corporations, and in-kind donations to support its mission of providing service dogs to those in need. Learn more about America’s VetDogs or the Guide Dog Foundation by visiting VetDogs.org or GuideDog.org. About America’s VetDogs Since 2003, America’s VetDogs (www.VetDogs.org) has trained and placed guide and service dogs to provide independence, enhanced mobility, and companionship to veterans with disabilities from all eras. In 2015, VetDogs opened its programs to first responders, including fire, police, and emergency medical personnel.  America’s VetDogs is a 501(c)(3) not-for-profit organization founded by the Guide Dog Foundation and serves clients from across the United States. VetDogs relies on contributions from generous individuals, corporations, service clubs, and foundations to fund its mission to help those who have served our country live with dignity and independence. It costs more than $50,000 to breed, raise, train, and place one assistance dog, but America’s VetDogs provides its services completely free of charge to the individual. America’s VetDogs has been accredited by both the International Guide Dog Federation and Assistance Dogs International. Attachment KLĒNR Soaps & Sundries Donates Two Years’ Worth of Premium Soaps to America’s VetDogs CONTACT: Allison Storck Guide Dog Foundation 6313342615 allison@guidedog.org The post KLĒNR Soaps & Sundries Donates Two Years’ Worth of Premium Soaps to America’s VetDogs appeared first on ForexTV.

Read More

Palm Oil Trade Slightly Lower

Palm oil prices in Malaysia have seen a slight decline, currently stabilizing just under MYR 3,930 per tonne. This follows an increase in the previous session due to expectations of rising inventory levels. According to a Reuters forecast, palm oil stocks rose for the third consecutive month in May, supported by a modest production recovery. Adding pressure on the market are declines in competing edible oils on the Chicago and Dalian exchanges. Palm oil has faced difficulty in recovering from the seven-month lows recorded in early May. This is due to factors such as favorable weather conditions, replanting activities, and improved practices among smallholder farmers, all of which are anticipated to boost production in the coming months. However, a limiting factor to the decline is the reported surge in demand from India, the largest palm oil importer, where imports reached a six-month peak in May following a previously subdued purchasing phase. To combat inflation and ensure adequate supply, India reduced import duties on crude edible oils, including palm oil, by half to 10% last week. On the export side, May saw robust performance, with cargo surveyors reporting shipment growth ranging from 13.2% to 17.9%. The material has been provided by InstaForex Company - www.instaforex.com The post Palm Oil Trade Slightly Lower appeared first on ForexTV.

Read More

Sweden’s Services Sector Rebounds as PMI Hits 50.8 in May

Sweden's services sector is showing signs of recovery, with the Purchasing Managers' Index (PMI) rising from 48.7 in April to 50.8 in May, as reported on June 4, 2025. This upbeat turn marks a crucial shift from contraction to expansion, symbolizing renewed vitality in the nation's services industry. The May PMI indicates growth, pulling ahead from the previous month's indicator which pointed to successive declines. April's PMI had dropped to 48.7, signaling contraction, but May's leap to 50.8 suggests a return to positive activity levels, reflecting growing demand across key service areas. This development is crucial for Sweden's economic outlook, as a PMI above 50 typically indicates expansion. The transition from April’s contraction strongly suggests the services sector is gaining momentum, potentially stabilizing the broader economy in the face of global economic uncertainties. Investors and businesses will closely watch if this growth trend continues in the following months, contributing to Sweden’s economic resilience. The material has been provided by InstaForex Company - www.instaforex.com The post Sweden’s Services Sector Rebounds as PMI Hits 50.8 in May appeared first on ForexTV.

Read More

LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities

LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities London, 4 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into a license agreement with Bayer HealthCare LLC, granting LIfT access to Bayer’s state-of-the-art Co.Lab facilities in Cambridge, Massachusetts – one of the world’s leading hubs for biotech innovation. This agreement provides LIfT with advanced infrastructure and shared services in a highly collaborative research environment, accelerating the development of its Immuno-Modulatory Alpha Neutrophil (IMAN) platform designed to overcome treatment resistance in solid tumours. “We see a strong strategic fit with The Bayer Group who have supported using cell therapies to replace dysfunctional cell types in the body in other therapeutic settings, and have developed the world-class facilities and expertise to cost-effectivenely deliver those therapies that we can now look to benefit from. The Bayer Co.Lab offers a unique environment designed to support our kind of biotech innovation, and strengthen our transatlantic presence as we expand as a clinical stage company,” said Alex Blyth, Chief Executive Officer of LIfT Biosciences. Fiona Mack, Head Co.Lab Cambridge at Bayer HealthCare LLC said: “The Co.Lab was created to provide cutting-edge biotech companies with the space, resources and network they need to accelerate their research and development. Co.Lab portfolio companies have been selected by a panel of experts within Bayer based upon the scientific merit and potential to substantially impact healthcare. LIfT, with its novel immunotherapy approach, exemplifies the type of company and innovative science that we aim to support and we believe they will be a great fit in our collaborative environment.” As part of the agreement, LIfT will gain access to a cutting-edge innovation space designed to support the unique needs of early-stage biotechs, with the flexibility to expand into larger “pods” or private lab areas as operations grow. LIfT will also benefit from centralised procurement and operational support, enabling the team to focus on advancing its IMAN platform efficiently and safely. About LIfT BioSciencesLIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by reconstituting immune competence. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) kill in a non-antigen specific manner and turn the tumour microenvironment against the tumour to give a durable total immune response and lasting immunity. The patented breakthrough N-LIfT platform is produced using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering. The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered IMAN immunotherapies to destroy a range of solid tumours. See www.LIfTBiosciences.com Further informationInvestors:Alex Blyth ablyth@LIfTBioSciences.com Media:ICR Healthcare Lindsey Neville, Namrata Taak, Evi Useh liftbiosciences@icrhealthcare.com The post LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities appeared first on ForexTV.

Read More

EPSO-G announces audited Sustainability Performance Report for 2024

EPSO-G (company code: 302826889, registered office address Laisvės pr. 10, Vilnius, Lithuania) (hereinafter - the Group) announces the 2024 Sustainability Performance Report (the Performance Report), including an Independent Limited Assurance Report. The Independent Limited Assurance of the Performance Report has been carried out by PricewaterhouseCoopers.  EPSO-G issued a EUR 75 million sustainability-linked bond ISIN LT0000406530 (hereinafter - the Bond prospectus) on 7 June 2022 (EUR 75,000,000 3.117 per cent. Senior Unsecured Sustainability-Linked Notes due 2027). Under the terms of the Bond, EPSO-G committed to achieving sustainability performance target (SPT1) to reduce its Scope 1 and Scope 2 GHG emissions (tCO2e) by 30% by 2026, compared to the 2019 baseline and SPT2 - ensure that the amount of energy not supplied (hereinafter - ENS) does not exceed 136.255 MWh in the period 2022-2026. PricewaterhouseCoopers has assessed the calculation and disclosure of Scope 1 and Scope 2 GHG emissions, and ENS indicator. The audit firm confirmed in an independent limited assurance report that the EPSO-G Group has calculated the two key performance indicators for 2024 in compliance with the criteria for disclosure of the sustainability indicators.  The Performance Report provides the latest information on the progress of the Group's key sustainability-linked performance targets and its indicators in the implementation of both the 2022 EPSO-G Sustainability-linked Finance Framework and the commitments made by EPSO-G under the Bond prospectus. This Performance Report should be read in conjunction with the EPSO-G 2024 consolidated management report (hereinafter - Management Report), which contains information relating to sustainability and other significant events affecting the Group. The Management Report is presented together with the independent auditor's report on the audit of the separate and consolidated financial statements and the independent practitioner's limited assurance report on the EPSO-G consolidated sustainability statement for the year ended December 31, 2024. The EPSO-G group of companies consists of the holding company EPSO-G and its five direct subsidiaries Amber Grid, Baltpool, Energy Cells, Litgrid and Tetas. EPSO-G and its Group companies also hold shares in Rheinmetall Defence Lietuva, GET Baltic, Baltic RCC OÜ and TSO Holding AS. The rights and obligations of the sole shareholder of EPSO-G are exercised by the Ministry of Energy of the Republic of Lithuania. For more information Gediminas Petrauskas, Communications Partner at EPSO-G Tel. +370 610 63306, e-mail gediminas.petrauskas@epsog.lt Attachment Darnumo_rodiklių_pažangos_ataskaita_2024_EN The post EPSO-G announces audited Sustainability Performance Report for 2024 appeared first on ForexTV.

Read More

Nokia Corporation – Managers’ transactions (Hotard)

Nokia CorporationManagers’ transactions4 June 2025 at 8:30 EEST Nokia Corporation - Managers' transactions (Hotard) Transaction notification under Article 19 of EU Market Abuse Regulation. The acquisition was conducted in accordance with the co-investment based long-term incentive arrangement.____________________________________________ Person subject to the notification requirementName: Hotard, Justin         Position: Chief Executive Officer Issuer: Nokia CorporationLEI: 549300A0JPRWG1KI7U06 Notification type: INITIAL NOTIFICATIONReference number: 110867/5/4____________________________________________ Transaction date: 2025-06-03Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009000681Nature of the transaction: ACQUISITION Transaction details(1): Volume: 609 274 Unit price: 4.6301 EUR Aggregated transactions(1): Volume: 609 274 Volume weighted average price: 4.6301 EUR About NokiaAt Nokia, we create technology that helps the world act together. As a B2B technology innovation leader, we are pioneering networks that sense, think and act by leveraging our work across mobile, fixed and cloud networks. In addition, we create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs, which is celebrating 100 years of innovation. With truly open architectures that seamlessly integrate into any ecosystem, our high-performance networks create new opportunities for monetization and scale. Service providers, enterprises and partners worldwide trust Nokia to deliver secure, reliable and sustainable networks today – and work with us to create the digital services and applications of the future. Inquiries:Nokia CommunicationsPhone: +358 10 448 4900Email: press.services@nokia.comMaria Vaismaa, Global Head of External Communications NokiaInvestor RelationsPhone: +358 931 580 507Email: investor.relations@nokia.com The post Nokia Corporation – Managers’ transactions (Hotard) appeared first on ForexTV.

Read More

Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers the same efficacy and safety demonstrated in available oral solution Evrysdi is the only non-invasive disease-modifying SMA treatment, with more than 18,000 people with SMA treated globally to date Basel, 04 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved a label extension for Evrysdi® (risdiplam) to include a new, room-temperature stable tablet for people living with spinal muscular atrophy (SMA). The 5mg tablet (approx. 6.5mm), which can either be swallowed whole or dispersed in water, can be taken with or without food and does not require refrigeration, when stored at room temperature. Administered at home, Evrysdi is the only non-invasive disease modifying treatment available for people living with SMA. “The new Evrysdi tablet with its flexible administration represents progress toward more versatile SMA disease management," said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development, Roche. “With over 18,000 people treated to date, Evrysdi’s proven efficacy, safety and convenience has significantly improved the course of disease for people living with SMA.” Evrysdi is designed to treat SMA by increasing and sustaining the production of SMN protein throughout the entire central nervous system (CNS) and in peripheral tissues. Together with this innovative mode of action, the new tablet formulation offers additional portability and convenience benefits for the thousands of people living with SMA, their families and caregivers. “We welcome the development of new treatment formulations that have the potential to further simplify disease management and care for people living with SMA,” Nicole Gusset, Chief Executive Officer, SMA Europe commented. “This is a disease requiring daily management, and it is paramount that people living with SMA, and those who care for them, are given options to optimise treatment administration.” The approval is based on data from a bioequivalence study (NCT04718181) evaluating the 5mg tablet formulation of Evrysdi, which can either be swallowed whole or dispersed in water. Results presented at SMA Europe’s 4th Scientific International Congress in 2024 demonstrated that the tablet formulation and original oral solution provided bioequivalence to Evrysdi, meaning individuals taking the tablet can expect the same established efficacy and safety as the oral solution. The 5mg tablet formulation is suitable for people two years of age or older, who weigh 20kg (44 lbs) or more and are able to swallow without the use of a feeding tube. The original oral solution will remain available for those on other doses of Evrysdi and for those who may prefer the oral solution. Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics. About Evrysdi® (risdiplam) Evrysdi is a survival motor neuron 2 (SMN2) splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to survival of motor neuron (SMN) protein deficiency. Evrysdi is administered daily at home or on the go, either in liquid form (by feeding tube or by mouth) or in the form of a tablet, which can either be swallowed whole or dispersed in water. Evrysdi is designed to treat SMA by increasing and sustaining the production of SMN protein in the CNS and peripheral tissues. SMN protein is found throughout the body and is critical for maintaining healthy motor neurons and core functions. Evrysdi was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) in 2017. In 2021, Evrysdi was awarded Drug Discovery of the Year by the British Pharmacological Society as well as the Society for Medicines Research Award for Drug Discovery. Evrysdi is currently approved in more than 100 countries, with more than 18,000 people with SMA treated globally. Evrysdi is currently being, or has been, evaluated in numerous global multicenter trials in people with SMA: FIREFISH (NCT02913482) – an open-label, two-part pivotal clinical trial in infants with Type 1 SMA. Infants were approximately 5.5 months of age (median) at the time of enrollment and of the 58 infants that completed the first year of treatment, 52 entered the open-label extension study. The study met its primary endpoint and has concluded after 5 years of follow up. SUNFISH (NCT02908685) – a two-part, double-blind, placebo-controlled pivotal study in people aged 2-25 years with Types 2 or 3 SMA. The study met its primary endpoint and has concluded after five years of follow up. JEWELFISH (NCT03032172) – an open-label exploratory trial designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics in people with SMA aged 6 months to 60 years who received other investigational or approved SMA therapies prior to receiving Evrysdi. The study has completed recruitment (n=174). RAINBOWFISH (NCT03779334) – an open-label, single-arm, multicenter study, investigating the efficacy, safety, pharmacokinetics, and pharmacodynamics of Evrysdi in babies (n=26), from birth to 6 weeks of age (at first dose) with genetically diagnosed SMA who are not yet presenting with symptoms. The study met its primary endpoint. MANATEE (NCT05115110) – a Phase II/III clinical study to evaluate the safety and efficacy of GYM329 (RG6237), an anti-myostatin molecule targeting muscle growth, in combination with Evrysdi for the treatment of SMA in patients 2-10 years of age. The FDA Office of Orphan Products Development granted GYM329 Orphan Drug Designation for the treatment of patients with SMA in December 2021. The study is currently recruiting. HINALEA 1 (NCT05861986) and HINALEA 2 (NCT05861999) – Phase IV clinical studies to evaluate the effectiveness and safety of Evrysdi in patients under 2 years of age at enrollment, who received onasemnogene abeparvovec gene therapy either pre-symptomatically or post-symptomatically, following a genetically confirmed diagnosis of 5q–autosomal recessive SMA. The studies are currently recruiting. PUPFISH (NCT05808764) – a Phase II, open-label study to investigate the pharmacokinetics and safety of Evrysdi in babies with SMA who are under 20 days of age (at first dose). The study is currently recruiting. About SMASMA is a severe, progressive neuromuscular disease that can be fatal. It affects approximately one in 10,000 babies and is the leading genetic cause of infant mortality. SMA is caused by a mutation of the survival motor neuron 1 (SMN1) gene, which leads to a deficiency of SMN protein. This protein is found throughout the body and is essential to the function of nerves that control muscles and movement. Without it, nerve cells cannot function correctly, leading to muscle weakness over time. Depending on the type of SMA, an individual’s physical strength and their ability to walk, eat or breathe can be significantly diminished or lost. About Roche in NeuroscienceNeuroscience is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Roche is investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About RocheFounded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com Hans Trees, PhDPhone: +41 79 407 72 58 Sileia UrechPhone: +41 79 935 81 48   Nathalie AltermattPhone: +41 79 771 05 25 Lorena CorfasPhone: +41 79 568 24 95   Simon GoldsboroughPhone: +44 797 32 72 915 Karsten KleinePhone: +41 79 461 86 83   Nina MählitzPhone: +41 79 327 54 74 Kirti PandeyPhone: +49 172 6367262   Yvette PetillonPhone: +41 79 961 92 50 Dr Rebekka SchnellPhone: +41 79 205 27 03 Attachment Media Release Evrysdi Tablet EC Approval English The post Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA) appeared first on ForexTV.

Read More

WISeKey International Holding Ltd Announces Adjournment of 2025 Annual General Meeting

WISeKey International Holding Ltd Announces Adjournment of 2025 Annual General Meeting Zug, Switzerland, June 4, 2025 – Ad-Hoc announcement pursuant to Art. 53 of SIX Listing Rules – WISeKey International Holding Ltd. (“WISeKey” or the “Company”) (SIX: WIHN, NASDAQ: WKEY), leading global cybersecurity, blockchain, and IoT company, announced today that the Board of Directors has decided, for logistical reasons, to ajourn the 2025 Annual General Meeting of Shareholders (“AGM“) from June 19, 2025, 2:00 p.m. Swiss time, to June 27, 2025, at 2:00 p.m. Swiss time. The venue of the 2025 AGM will remain the offices of Homburger AG, Prime Tower, Hardstrasse 201, 8005 Zurich, Switzerland. Admittance to the 2025 AGM will start at 1:30 p.m. Swiss time. Other than the date of the AGM, nothing will change. In particular, the items on the agenda of the AGM and the related proposals of the Board of Directors remain unchanged. About WISeKeyWISeKey International Holding Ltd (“WISeKey”, SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) WISe.ART Corp which focuses on trusted blockchain NFTs and operates the WISe.ART marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN platform. Each subsidiary contributes to WISeKey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using Blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. The company’s semiconductors generate valuable Big Data that, when analyzed with AI, enable predictive equipment failure prevention. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, Blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey’s strategic direction and its subsidiary companies, please visit www.wisekey.com. Press and investor contacts: WISeKey International Holding Ltd Company Contact:  Carlos MoreiraChairman & CEOTel: +41 22 594 3000info@wisekey.com WISeKey Investor Relations (US) Contact:  Lena CatiThe Equity Group Inc.Tel: +1 212 836-9611lcati@theequitygroup.com Disclaimer:This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FinSa's predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey. The post WISeKey International Holding Ltd Announces Adjournment of 2025 Annual General Meeting appeared first on ForexTV.

Read More

SIKA TO ADVANCE THE DIGITAL TRANSFORMATION OF THE CONSTRUCTION INDUSTRY WITH GIATEC

SIKA TO ADVANCE THE DIGITAL TRANSFORMATION OF THE CONSTRUCTION INDUSTRY WITH GIATEC Sika has made a strategic investment in Giatec™ Scientific Inc., a global leader in digital concrete technology platforms specializing in smart testing and AI-driven solutions, headquartered in Canada. Giatec develops advanced sensors, software, and data analytics tools to optimize concrete quality, durability, and sustainability, from production and delivery to placement. This investment represents a significant milestone in Sika’s overall digital strategy, helping the construction industry to improve efficiency and reduce carbon footprint. One key challenge in concrete production is the tendency to overdesign concrete mixes due to raw material fluctuations. With Giatec’s AI-powered concrete mix optimization and Sika’s advanced admixture technologies, the amount of cement and aggregates used can be analyzed and optimized precisely. This results in significant cost savings and a reduction in CO₂ emissions. In alignment with Sika’s strategy to enhance its digital ecosystem, this partnership will accelerate the adoption of smart technologies. By integrating software, sensors, and data platforms, it aims to empower customers to monitor, optimize, and predict various aspects of construction projects for better outcomes. Ivo Schaedler, Head of Construction Sika: "Sika is excited to shape the future of the concrete industry through digital transformation, working closely with Giatec and its network of strategic global partners like Heidelberg Materials. By leveraging digital innovation, we are providing the construction industry with unparalleled data-driven insights that improve sustainability and performance, and enable the next level of modern construction." "We are pleased to strategically partner with Sika as we work together to redefine the future of AI-powered concrete construction," said Pouria Ghods, CEO and Co-founder of Giatec. "With Sika’s global reach and proven leadership in the industry, we are uniquely positioned to scale our smart technologies worldwide, empowering the construction sector with data-driven solutions that enhance efficiency, durability, and sustainability on a global scale." GIATEC CORPORATE PROFILEGiatec is a global company revolutionizing the concrete industry by bringing smart testing technologies and real-time collection and analysis of concrete data from production and delivery to placement. Giatec's suite of hardware & software products has leveraged advanced technologies such as Artificial Intelligence (AI), and Internet of Things (IoT), including; wireless concrete sensors, mobile apps, and advanced non-destructive technologies (NDT) to drive innovation throughout concrete's lifecycle and reduce concrete's carbon footprint. For more information visit https://www.giatecscientific.com/  SIKA CORPORATE PROFILESika is a specialty chemicals company with a globally leading position in the development and production of systems and products for bonding, sealing, damping, reinforcing, and protection in the building sector and industrial manufacturing. Sika has subsidiaries in 102 countries around the world and, in over 400 factories, produces innovative technologies for customers worldwide. In doing so, it plays a crucial role in enabling the transformation of the construction and transportation sector toward greater environmental compatibility. With more than 34,000 employees, the company generated sales of CHF 11.76 billion in 2024. CONTACTDominik SlappnigCorporate Communications &Investor Relations+41 58 436 68 21slappnig.dominik@ch.sika.com The media release can be downloaded from the following link:Media Release The post SIKA TO ADVANCE THE DIGITAL TRANSFORMATION OF THE CONSTRUCTION INDUSTRY WITH GIATEC appeared first on ForexTV.

Read More

Allegations of Ethical Violations Lead to Call for Disqualification of Counsel in Dickey’s Restaurants Litigation

Dallas, TX, June 04, 2025 (GLOBE NEWSWIRE) -- Today,  Lynn, Pinker, Hurst & Schwegmann has filed a motion to disqualify the Zarco law firm from acting as counsel in a matter involving Dickey’s Restaurants, Inc in the United States District Court Northern District Of Illinois Eastern Division. The challenge cites alleged egregious and intentional violations of Rules 4.2, 8.4, and 3.7 of the American Bar Association Model Rules of Professional Conduct. The motion centers around the Zarco firm leading a coordinated and unwarranted attack on Dickey’s Restaurants to the firm’s financial benefit. Allegations include Zarco coordinating and funding baseless litigation by disgruntled franchisees, driving negative publicity, and encouraging franchisees to violate their agreements. Based on information, it is believed that the firm has spent money to attempt to induce franchisees to hire the firm to file unfounded claims. The federal court motion to disqualify Zarco includes accusations that Zarco sued a former Dickey’s employee to attempt to force the former employee to testify against Dickey’s to get out of the lawsuit.  On April 11, 2025, Zarco attorneys reportedly encouraged a client to contact the individual directly, demanding he contact the firm and “work with us.” This contact is alleged to be a violation of ethical rules and tantamount to witness tampering. Click here to listen to the audio file from filed motion transcript.  The complaint further states that the firm subpoenaed the individual for an arbitration trial but then refused to call them to testify, aiming instead to coerce them into changing their testimony privately. These actions are described as professional misconduct aimed at gaining an unfair advantage and threatening the integrity of the legal process. The motion case is: 1:25-cv-02166 Document #: 30. Lynn, Pinker, Hurst, & Schwegmann Lynnllp.com Media Contact: Monica Cordova monica@allynmedia.com CONTACT: Louisa Garrett lgarrett@dickeys.com The post Allegations of Ethical Violations Lead to Call for Disqualification of Counsel in Dickey’s Restaurants Litigation appeared first on ForexTV.

Read More

Bitcoin ‘Going To Take Over’—Tesla CEO Elon Musk Backs Shock $40 Trillion U.S. Dollar Collapse Warning Amid Price Boom

Tesla billionaire Elon Musk has restarted his campaign against out of control U.S. government spending, backing a warning that bitcoin could “take over” from the U.S. Read Full Story The post Bitcoin ‘Going To Take Over’—Tesla CEO Elon Musk Backs Shock $40 Trillion U.S. Dollar Collapse Warning Amid Price Boom appeared first on ForexTV.

Read More

Showing 721 to 740 of 2167 entries

You might be interested in the following

Keyword News · Community News · Twitter News

DDH honours the copyright of news publishers and, with respect for the intellectual property of the editorial offices, displays only a small part of the news or the published article. The information here serves the purpose of providing a quick and targeted overview of current trends and developments. If you are interested in individual topics, please click on a news item. We will then forward you to the publishing house and the corresponding article.
· Actio recta non erit, nisi recta fuerit voluntas ·